Change in mTSS† | Placebo/adalimumab‡ N (%) | Adalimumab N (%) | 95% CI§ |
Baseline to week 24, N | 128 | 115 | |
Decrease/no change | 90 (70.3) | 103 (89.6) | 82.5 to 94.5 |
Increase | 38 (29.7) | 12 (10.4) | 5.5 to 17.5 |
Baseline to week 48, N | 128 | 115 | |
Decrease/no change | 94 (73.4) | 102 (88.7) | 81.4 to 93.8 |
Increase | 34 (26.6) | 13 (11.3) | 6.2 to 18.6 |
Week 24 to week 48, N | 128 | 115 | |
Decrease/no change | 105 (82.0) | 99 (86.1) | 78.4 to 91.8 |
Increase | 23 (18.0) | 16 (13.9) | 8.2 to 21.6 |
Baseline to week 144, N | 128 | 115 | |
Decrease/no change | 88 (68.8) | 91 (79.1) | 70.6 to 86.1 |
Increase | 40 (31.3) | 24 (20.9) | 13.9 to 29.4 |
Week 24 to week 144, N | 128 | 115 | |
Decrease/no change | 99 (77.3) | 89 (77.4) | 68.7 to 84.7 |
Increase | 29 (22.7) | 26 (22.6) | 15.3 to 31.3 |
Week 48 to week 144, N | 128 | 115 | |
Decrease/no change | 104 (81.3) | 92 (80.0) | 71.5 to 86.9 |
Increase | 24 (18.8) | 23 (20.0) | 13.1 to 28.5 |
Decrease is <−0.5 change; no change was −0.5 to 0.5 change; increase was >0.5 change.
*Patients included in this analysis are those who had a radiographic measure at baseline, week 24, week 48 and at week 96 or week 144. Data are imputed; for patients who did not have a week 144 modified total Sharp score (mTSS), the week 96 mTSS was used.
†Data are imputed; for patients who did not have a week 144 mTSS, the week 96 mTSS was used.
‡Patients who were randomly assigned to receive placebo during the double-blind phase of the study began receiving open-label adalimumab 40 mg every other week starting at week 24.
§An exact 95% CI was constructed based on the binomial distribution for the adalimumab group.
ADEPT, Adalimumab Effectiveness in Psoriatic Arthritis Trial.